Aura Announces Appointment of Alain Dobkin to its Board of Directors
2019年3月26日 - 9:00PM
Aura Health Inc. (the “
Company” or
“
Aura”) (
CSE:BUZZ) is pleased to
announce the appointment of Alain Dobkin to its board of directors,
subject to regulatory approval. Alain is a private equity investor
with more than 20 years of investment and advisory experience,
including 13 years with Citigroup Investment Bank in New York and
Tel Aviv. Additionally, he was the Director of Citigroup’s Israel
Investment Bank, where he served as advisor on strategic mergers
and acquisitions and equity and debt capital raising transactions
from both public and private markets globally. Alain brings a
wealth of experience in global and Israeli finance and M&A
having managed transactions with aggregate value of ~US$40 billion.
To make room for Mr. Dobkin, Chris Carl has
volunteered to step down as President and from Aura’s board to
focus on his role as CEO of DigiCrypts.
Daniel Cohen, Aura’s CEO, commented, “Alain
brings significant pedigree to Aura’s board of directors both from
a financial perspective and a knowledge of Israeli and European
markets. As we continue to build out our asset base in Israel and
Europe, Alain being situated in Tel Aviv will be a tremendous asset
to our business. We wish the best of luck to Chris in his new
endeavor.”
About Aura Health Inc.
Aura Health is building an international network
of vertically integrated cannabis assets. Through a product line of
cannabis-infused edible products and oil extracts, Aura is
dedicated to building a high margin downstream business in the
medical marijuana sector. The Company holds debt convertible into
54% equity of HolyCanna, a cultivation and nursery license holder
in Israel. Aura has also entered into a definitive agreement to
acquire 80% of Pharmadrug, a German medical cannabis and
pharmaceutical distributor, as well as a binding letter of intent
to purchase 57% of CannabiSendak, the builder of a network of
high-profile dispensaries in Israel. The Company also owns a 30%
interest in four medical marijuana clinics in the U.S. Sun
Belt.
For further information, please
contact:
Daniel Cohen, CEO Aura Health
Inc. (647) 202-1824
David Posner, ChairmanAura
Health Inc. (647) 985-6727
Caution Regarding Forward-Looking
Information:
THE CANADIAN SECURITIES EXCHANGE HAS NOT
REVIEWED NOR DOES IT ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR
ACCURACY OF THIS RELEASE.
This news release may contain “forward-looking
information” within the meaning of applicable Canadian securities
laws. Generally, forward-looking information can be identified by
the use of words and phrases such as “plans”, “expects”,
“continues”, “intends”, “anticipates”, or “believes”, or variations
of such words and phrases indicating that certain actions, events
or results “may”, “could”, “would”, “might” or “will” be taken or
occur. These statements should not be read as guarantees of future
performance or results. Such statements involve known and unknown
risks, uncertainties and other factors that may cause actual
results, performance or achievements to be materially different
from those implied by such statements. Such statements include
those relating to regulatory approval of a new director and the
Company’s future expansion plans in Israel and Europe. There is no
certainty that any of these events will occur. Although such
statements are based on management's reasonable assumptions, there
can be no assurance that such assumptions will prove to be
correct.
Additionally, there are known and unknown risk
factors which could cause the Company's actual results, performance
or achievements to be materially different from any future results,
performance or achievements expressed or implied by the
forward-looking information contained herein. These risks and
uncertainties include, without limitation, regulatory approval,
rapidly developing global regulatory regimes relating to cannabis,
and/or inability to successfully execute intended strategies and
business objectives. All forward-looking information herein is
qualified in its entirety by this cautionary statement, and the
Company disclaims any obligation to revise or update any such
forward-looking information, except as required by applicable
securities laws.
The Company's securities have not been
registered under the U.S. Securities Act of 1933, as amended (the
"U.S. Securities Act"), or applicable state securities laws, and
may not be offered or sold to, or for the account or benefit of,
persons in the United States or "U.S. Persons", as such term is
defined in Regulation S under the U.S. Securities Act, absent
registration or an applicable exemption from such registration
requirements. This press release shall not constitute an offer to
sell or the solicitation of an offer to buy nor shall there be any
sale of the securities in the United States or any jurisdiction in
which such offer, solicitation or sale would be unlawful.
Pharmadrug (CSE:BUZZ)
過去 株価チャート
から 11 2024 まで 12 2024
Pharmadrug (CSE:BUZZ)
過去 株価チャート
から 12 2023 まで 12 2024